|

Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation

RECRUITINGN/ASponsored by University of Aarhus
Actively Recruiting
PhaseN/A
SponsorUniversity of Aarhus
Started2022-11-14
Est. completion2025-06-01
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04798898

Summary

To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with colorectal liver metastases planned for resection
* At least one tumor size \>=3cm
* Performance status 0-1

Exclusion Criteria:

* Liver cirrhosis
* Extrahepatic metastases that can not be addressed curatively
* Other malignant diseases within 5 years prior to diagnosis
* Prior RFA treatment

Conditions3

CancerLiver CancerLiver Metastasis Colon Cancer

Browse More Trials

Cancer trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.